CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 target
Drug / intervention
cyclophosphamide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002553
NCT00002553Phase 2Completed

TREATMENT OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING MARROW TRANSPLANTATION FROM UNRELATED DONORS MATCHED FOR HLA OR INCOMPATIBLE FOR ONE HLA LOCUS ANTIGEN

Fred Hutchinson Cancer Center·interventional·Posted Apr 26, 2004·Updated Nov 30, 2011

In Brief

A Phase 2 clinical trial evaluating cyclophosphamide, allogeneic bone marrow transplantation, and 1 other intervention for Leukemia and Lymphoma. Completed, enrolled 50 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation using unrelated bone marrow donors in treating patients who have hematologic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Lymphoma
CountriesUnited States

Timeline

Phase 2CompletedFinished
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 26, 2004
Enrollment StartAug 1, 1990
Study CompletionJun 1, 2003
TodayJul 2, 2026
Posted 22.2 years ago

Interventions

cyclophosphamidedrug

allogeneic bone marrow transplantationprocedure

low-LET cobalt-60 gamma ray therapyradiation